SCHEMBL4814151

SCHEMBL4814151

COc1cc2c(cc1O)C(C)(C)c1c(-c3ccc(C#N)nc3)nn(COCC[Si](C)(C)C)c1-2

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 13/20 0.40
PDE10A Q9Y233 1/20 0.36
AURKA O14965 1/20 0.36
JAK2 O60674 1/20 0.36
CHEK2 O96017 1/20 0.36
CSF1R P07333 1/20 0.36
RPS6KB1 P23443 1/20 0.36
MARK3 P27448 1/20 0.36
FLT3 P36888 1/20 0.36
RPS6KA3 P51812 1/20 0.36
AURKB Q96GD4 1/20 0.36
PIK3CA P42336 1/20 0.35
DGAT1 O75907 1/20 0.35
APLNR P35414 2/20 0.33
FGFR1 P11362 1/20 0.31
FGFR2 P21802 1/20 0.31
FGFR4 P22455 1/20 0.31
FGFR3 P22607 1/20 0.31
TNF P01375 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4811592 0.87 CHEK1 (0.36) CHEK1PIK3CADGAT1APLNR
SCHEMBL4816587 0.85 CHEK1 (0.48) CHEK1AURKAJAK2CHEK2CSF1R
SCHEMBL4814671 0.78 SNCA (0.30) DGAT1
SCHEMBL4806272 0.76 CHEK1 (0.52) CHEK1AURKAJAK2CHEK2CSF1R
SCHEMBL4806341 0.76 CHEK1 (0.57) CHEK1PDE10AAURKAJAK2CHEK2
SCHEMBL4818711 0.73 CHEK1 (0.39) CHEK1AURKAJAK2CHEK2CSF1R
SCHEMBL4817374 0.72 CHEK1 (0.54) CHEK1AURKAAURKB
SCHEMBL4814318 0.71 CHEK1 (0.39) CHEK1PDE10ADGAT1
SCHEMBL4813087 0.71 CHEK1 (0.42) CHEK1AURKACHEK2CSF1RRPS6KB1
SCHEMBL4813158 0.71 CHEK1 (0.40) CHEK1DGAT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7320986-B2 Fused tri and tetra-cyclic pyrazole kinase inhibitors ABBOTT LABORTORIES (US) 2008-01-22 US disclosed
US-20040259904-A1 Fused tri and tetra-cyclic pyrazole kinase inhibitors ABBVIE INC. 2004-12-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040259904-A1 Fused tri and tetra-cyclic pyrazole kinase inhibitors TK1, MAP3K19, MAP3K20 CHEK1 73/4885PDE10A 1342/4885AURKA 314/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.